Search results for "MESH: Antifungal Agents"

showing 2 items of 2 documents

Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study

2011

Objectives: To provide a global, up-to-date picture of the prevalence, treatment, and outcomes of Candida bloodstream infections in intensive care unit patients and compare Candida with bacterial bloodstream infection. Design: A retrospective analysis of the Extended Prevalence of Infection in the ICU Study (EPIC II). Demographic, physiological, infection-related and therapeutic data were collected. Patients were grouped as having Candida, Gram-positive, Gram-negative, and combined Candida/bacterial bloodstream infection. Outcome data were assessed at intensive care unit and hospital discharge. Setting: EPIC II included 1265 intensive care units in 76 countries. Patients: Patients in partic…

Candida albicanMaleAntifungal AgentsIron metabolism Pathogenesis and modulation of inflammation [IGMD 7]Settore MED/41 - AnestesiologiaCritical Care and Intensive Care Medicinelaw.inventionEchinocandinschemistry.chemical_compound0302 clinical medicineRetrospective StudieCaspofunginlawCandida albicansPrevalenceAntifungal Agent030212 general & internal medicineCandida albicansFluconazoleMESH: SepsisFungemiaintensive careMedicine(all)MESH: AgedCross Infection0303 health scienceseducation.field_of_studyMESH: Middle AgedfungemiabiologyCandidiasisMiddle AgedIntensive care unitMESH: Candidiasisbacteremia; epidemiology; fungemia; intensive care; outcome assessment (health care); Aged; Antifungal Agents; Candida albicans; Candidiasis; Cross Infection; Echinocandins; Female; Fluconazole; Humans; Intensive Care Units; Lipopeptides; Male; Middle Aged; Prevalence; Retrospective Studies; Sepsis; Critical Care and Intensive Care Medicine3. Good healthIntensive Care Unitsbacteremia epidemiology fungemia intensive care outcome assessment (health care)CandidiasiMESH: FluconazoleepidemiologyFemaleHumanmedicine.drugmedicine.medical_specialtySepsiIntensive Care UnitPopulationLipopeptides03 medical and health sciencesSepsisIntensive caremedicineHumansEchinocandinbacteremiaIntensive care medicineeducationMESH: PrevalenceAgedRetrospective Studiesoutcome assessment (health care)MESH: Humans030306 microbiologybusiness.industryMESH: Candida albicansMESH: EchinocandinsMESH: Cross InfectionMESH: Retrospective Studies[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: Antifungal Agentsmedicine.diseasebiology.organism_classificationMESH: MalechemistryBacteremiaMESH: Intensive Care UnitsCaspofunginbusinessMESH: FemaleFluconazole
researchProduct

Emergence of Aspergillus fumigatus azole resistance in azole-naïve patients with chronic obstructive pulmonary disease and their homes.

2017

Azole-resistant Aspergillus fumigatus (ARAF) has been reported in patients with chronic obstructive pulmonary disease (COPD) but has not been specifically assessed so far. Here, we evaluated ARAF prevalence in azole-naïve COPD patients and their homes, and assessed whether CYP51A mutations were similar in clinical and environmental reservoirs. Sixty respiratory samples from 41 COPD patients with acute exacerbation and environmental samples from 36 of these patient's homes were prospectively collected. A. fumigatus was detected in respiratory samples from 11 of 41 patients (27%) and in 15 of 36 domiciles (42%). Cyp51A sequencing and selection on itraconazole medium of clinical (n = 68) and e…

Drug Resistance Fungal -- genetics0301 basic medicineAzolesMaleAntifungal AgentsExacerbationMESH: Fungal Proteins/isolation & purification[SDV]Life Sciences [q-bio]Colony Count MicrobialAspergillus fumigatusMESH: Aspergillus fumigatus/drug effectsMESH: Cytochrome P-450 Enzyme System/drug effectsMESH: GenotypePulmonary Disease Chronic ObstructivedwellingCytochrome P-450 Enzyme SystemGenotypePulmonary Disease Chronic Obstructive -- microbiologyPrevalenceProspective Studieschemistry.chemical_classificationMESH: AgedCOPDAzole-resistanceMESH: Middle AgedbiologyMESH: Drug Resistance Fungal/geneticsMold environmental exposureSciences bio-médicales et agricolesMiddle Aged3. Good healthMESH: Pulmonary Disease Chronic Obstructive/microbiology*MESH: Housing[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyAir Pollution IndoorAcute DiseaseDisease ProgressionMESH: Acute DiseaseMESH: Cytochrome P-450 Enzyme System/isolation & purificationMESH: Disease ProgressionFemalemedicine.drugmedicine.medical_specialtyEnvironmental EngineeringGenotypeItraconazoleMESH: Fungal Proteins/drug effects030106 microbiologyAspergillus fumigatus -- drug effects -- genetics -- isolation & purificationMESH: Azoles/pharmacology*Fungal Proteins -- drug effects -- isolation & purificationchronic obstructive pulmonary diseaseMicrobiologyFungal Proteins03 medical and health sciencesazole resistanceMESH: Air Pollution Indoor/analysis*Drug Resistance FungalInternal medicinemedicineCOPDHumansMESH: Aspergillus fumigatus/geneticsDwellingMESH: Colony Count MicrobialMESH: PrevalenceAgedAspergillusMESH: HumansAspergillus fumigatusAzoles -- pharmacologyelectrostatic dust collectorPublic Health Environmental and Occupational Healthmold environmental exposureElectrostatic dust collectorBuilding and Constructionmedicine.diseasebiology.organism_classificationMESH: MaleMESH: Prospective StudieschemistryCytochrome P-450 Enzyme System -- drug effects -- isolation & purificationHousingAzoleARAFMESH: Aspergillus fumigatus/isolation & purification*Antifungal Agents -- pharmacologyMESH: Antifungal Agents/pharmacology*MESH: FemaleAir Pollution Indoor -- analysisIndoor air
researchProduct